Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

Meta’s AI assistant now has one billion monthly active users across the company’s family of apps, CEO Mark Zuckerberg said Wednesday.

The Obesity Drugs Market is experiencing unprecedented growth, driven by increasing global obesity rates, sedentary ...

Glenmark Pharmaceuticals seeks licensing deal for ISB 2001 drug candidate, plans growth with semaglutide in India.

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

Biopharma Industry Landscape Report—uncover key trends in obesity, oncology, immunology, and AI, plus top stock picks and ...

As the U.S. stock market navigates through a period of slight declines ahead of Nvidia's earnings report, investors are closely watching major indices like the Dow Jones and S&P 500, which have shown ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states ...

Globalpharma, which is a wholly owned subsidiary of Dubai Investments, is laying the groundwork to manufacture generic versions of blockbuster drugs such as Ozempic, positioning itself ahead of ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, is honored to share that it was awarded ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...